Literature DB >> 20538859

Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Frank Wolschendorf1, Alexandra Duverger, Jennifer Jones, Frederic H Wagner, Jason Huff, William H Benjamin, Michael S Saag, Michael Niederweis, Olaf Kutsch.   

Abstract

Current antiretroviral therapy (ART) efficiently controls HIV-1 replication but fails to eradicate the virus. Even after years of successful ART, HIV-1 can conceal itself in a latent state in long-lived CD4(+) memory T cells. From this latent reservoir, HIV-1 rebounds during treatment interruptions. Attempts to therapeutically eradicate this viral reservoir have yielded disappointing results. A major problem with previously utilized activating agents is that at the concentrations required for efficient HIV-1 reactivation, these stimuli trigger high-level cytokine gene expression (hypercytokinemia). Therapeutically relevant HIV-1-reactivating agents will have to trigger HIV-1 reactivation without the induction of cytokine expression. We present here a proof-of-principle study showing that this is a possibility. In a high-throughput screening effort, we identified an HIV-1-reactivating protein factor (HRF) secreted by the nonpathogenic bacterium Massilia timonae. In primary T cells and T-cell lines, HRF triggered a high but nonsustained peak of nuclear factor kappa B (NF-kappaB) activity. While this short NF-kappaB peak potently reactivated latent HIV-1 infection, it failed to induce gene expression of several proinflammatory NF-kappaB-dependent cellular genes, such as those for tumor necrosis factor alpha (TNF-alpha), interleukin-8 (IL-8), and gamma interferon (IFN-gamma). Dissociation of cellular and viral gene induction was achievable, as minimum amounts of Tat protein, synthesized following application of a short NF-kappaB pulse, triggered HIV-1 transactivation and subsequent self-perpetuated HIV-1 expression. In the absence of such a positive feedback mechanism, cellular gene expression was not sustained, suggesting that strategies modulating the NF-kappaB activity profile could be used to selectively trigger HIV-1 reactivation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538859      PMCID: PMC2919022          DOI: 10.1128/JVI.00523-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes.

Authors:  Yefei Han; Kara Lassen; Daphne Monie; Ahmad R Sedaghat; Shino Shimoji; Xiao Liu; Theodore C Pierson; Joseph B Margolick; Robert F Siliciano; Janet D Siliciano
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

3.  Dynamics of HIV-1 recombination in its natural target cells.

Authors:  David N Levy; Grace M Aldrovandi; Olaf Kutsch; George M Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-09       Impact factor: 11.205

4.  Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Authors:  Joseph Kulkosky; Giuseppe Nunnari; Miguel Otero; Sandra Calarota; Geetha Dornadula; Hui Zhang; Anne Malin; Julie Sullivan; Yan Xu; Joseph DeSimone; Timothy Babinchak; John Stern; Winston Cavert; Ashley Haase; Roger J Pomerantz
Journal:  J Infect Dis       Date:  2002-10-29       Impact factor: 5.226

5.  Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.

Authors:  Chulhee Choi; Olaf Kutsch; Jinseu Park; Tong Zhou; Dai-Wu Seol; Etty N Benveniste
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

6.  The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation.

Authors:  Alexander Hoffmann; Andre Levchenko; Martin L Scott; David Baltimore
Journal:  Science       Date:  2002-11-08       Impact factor: 47.728

7.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  Determinants of the establishment of human immunodeficiency virus type 1 latency.

Authors:  Alexandra Duverger; Jennifer Jones; Jori May; Frederic Bibollet-Ruche; Frederic A Wagner; Randall Q Cron; Olaf Kutsch
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  Massilia jejuensis sp. nov. and Naxibacter suwonensis sp. nov., isolated from air samples.

Authors:  Hang-Yeon Weon; Seung-Hee Yoo; Soo-Jin Kim; Yi-Seul Kim; Rangasamy Anandham; Soon-Wo Kwon
Journal:  Int J Syst Evol Microbiol       Date:  2009-09-25       Impact factor: 2.747

10.  Characteristics of Massilia timonae and Massilia timonae-like isolates from human patients, with an emended description of the species.

Authors:  David Lindquist; Donna Murrill; W Patrick Burran; Gloria Winans; J Michael Janda; Will Probert
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

View more
  11 in total

Review 1.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

Review 3.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

Review 4.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.

Authors:  Christine Katlama; Steven G Deeks; Brigitte Autran; Javier Martinez-Picado; Jan van Lunzen; Christine Rouzioux; Michael Miller; Stefano Vella; Joern E Schmitz; Jeffrey Ahlers; Douglas D Richman; Rafick P Sekaly
Journal:  Lancet       Date:  2013-03-29       Impact factor: 79.321

5.  Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.

Authors:  M A Rochat; E Schlaepfer; R F Speck
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 6.  Facts and fiction: cellular models for high throughput screening for HIV-1 reactivating drugs.

Authors:  Vicente Planelles; Frank Wolschendorf; Olaf Kutsch
Journal:  Curr HIV Res       Date:  2011-12-01       Impact factor: 1.581

Review 7.  The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.

Authors:  Jonathan Karn
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

8.  Selected drugs with reported secondary cell-differentiating capacity prime latent HIV-1 infection for reactivation.

Authors:  Takao Shishido; Frank Wolschendorf; Alexandra Duverger; Frederic Wagner; John Kappes; Jennifer Jones; Olaf Kutsch
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

9.  GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death.

Authors:  Robert T Rydze; Nirjal Bhattarai; Jack T Stapleton
Journal:  Antivir Ther       Date:  2012-09-05

10.  Control of HIV latency by epigenetic and non-epigenetic mechanisms.

Authors:  Uri Mbonye; Jonathan Karn
Journal:  Curr HIV Res       Date:  2011-12-01       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.